Cathepsin S (CatS), a cysteine protease belonging to the papain family, has been proposed as an attractive therapeutic target for asthma 1 and autoimmune diseases 2 due to the fact that CatS is closely implicated in the process of antigen presentation. 3, 4 Indeed, it has been reported that inhibition of CatS decreases chronic inflammatory pain in a collageninduced arthritis (CIA) model of rheumatoid arthritis. 5 Thus, there is a growing interest among medicinal chemists to identify CatS inhibitors. Morpholineurea-leucine homophenylalanine vinyl sulfone 1 (LHVS, Figure 1 ) has been previously identified as a potent CatS inhibitor but limited selectivity for members of the cathepsin family. 6 A number of selective CatS inhibitors have been reported as potential therapeutic agents, including cyanopeptide-, pyrrolopyrimidine-, aminopyrimidine-, cyanopyrazolidine-based inhibitors. 7, 8 Although some CatS inhibitors are currently being evaluated in clinical trials, 9 potent and selective CatS inhibitors are still required. With respect to development of selective CatS inhibitors, we recently reported novel selective cathepsin S inhibitors based on a proline scaffold. 10 Following up on this work, we herein report the synthesis of a series of proline analogues with vinyl sulfone group, which is a key functional group of LHVS. We evaluated these novel compounds for their in vitro CatS inhibitory activity to investigate a structure-activity relationship (SAR).
The general synthetic procedure for preparing 4-sulfonyl substituted proline-derived analogues is summarized in Scheme 1. Mesylation of the commercially available proline analogue 2 was performed under Mitsunobu condition and subsequent nucleophilic substitution by a thiol afforded the thioether 4, which was converted to sulfone 5 by mCPBA oxidation. After deprotection of tert-Boc, acid chloride or anhydride were coupled with an amine 6 to provide the amide 7. Next, compound 7 was hydrolyzed and treated with vinyl sulfone amine 9 in the presence of EDCI and HOBt to yield the desired analogues (15-24). The synthetic route for compound 9 is illustrated in Scheme 2. Commercially available amino-alcohol 10 was protected with t-Boc group, followed by oxidation with Dess-Martin periodinane to furnish aldehyde 12 in high yield (85% over 2 steps).
Olefination of 12 with phosphonate 13 11 gave the required vinyl sulfone 14 and Boc deprotection provided the desired fragment 9. We attempted to modify a proline moiety to increase selectivity while retaining the vinyl sulfone, which is critical for activity of LHVS. In order to investigate SAR, the R 1 moiety was modified to various alkyl (15 -18) or aryl (19 and 20) substituents. All of the R 1 -modified analogues showed excellent IC 50 values for human CatS (hCat S) in the range of 1.2 to 2.6 nM, which was similar to LHVS (Table  1) . Likewise, most vinyl sulfone analogues showed better activity than the 2-acyl benzoxazole analogues that we previously reported. 10 We next evaluated the influence of R 2 -substituents on cathepsin S, for which R 1 were fixed as methyl group. Regioisomeric chlorophenyl derivatives 21-23 and the 4-biphenyl compound 24 exhibited inhibitory activity similar to the unsubstituted phenyl analogue 15. Several of the potent CatS inhibitors then were screened for inhibitory activity for cathepsin B and K to determine if they were selective for CatS (Table 2) . While LHVS showed potent inhibitory activity for CatK as well as CatS, the selected compounds did not inhibit CatB and CatK. CA-074 was used as a positive control for CatB. 13 In summary, we developed a series of novel vinyl sulfone tethered proline derivatives as potent CatS inhibitors. The representative compounds showed excellent in vitro activity and selectivity for CatS over CatB and CatK. Thus, these compounds could serve as leads for the development of CatS inhibitors. 
